Claritas Pharmaceuticals Inc V.CLAS.H

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe try reading the news release? Right your one of those

[AngelaL]

You are confusing vaccine design with vaccine development. Design of a vaccine to address the new mutants from Brazil and South Africa is a no-brainer: it would take a college level molecular biology student no more than a coupe hours because the mutations have been published. Development of such a vaccine is an entirely different matter - it will take about one year. This is because the introduction of those small changes to the current vaccine has broad ramifications. The folding (tertiary structure) of mRNA is highly variable and is entirely dependent upon its nucleotide sequence (primary structure). As folding shifts so do the epitopes that are conformational (ie the antigenic presentation to the immune system is based on tertiary structure, not primary structure). So the new vaccines may have all kinds of new problems. They may have folded in such a way that hides the immunodominant epitopes, in which case they may not elicit an effective immune response or any immune response at all. Second, the new conformational epitopes might elicit an immune response that cross-reacts with healthy tissue (this was the concern of the AstraZeneca vaccine when there were reports of transverse myelitis that led to paralysis). Since a vaccine may be expected to be administered to hundreds of millions of people, these safety considerations cannot be ignored. So regulatory agencies will not permit a new vaccine, even one with a single nucleotide change, to bypass the normal safeguards to ensure safety (ie requirement for studies of 20-40 thousand subjects). All in all, there is evidence that this virus is rapidly evolving through mutation. R-107 may be a game changing therapy because it doesn't depend on the ever-changing shape of the mutant spike proteins.